Sustained complete response to cytotoxic therapy and the PARP inhibitor veliparib in metastatic castration resistant prostate cancer – a case report

Sustained complete response to cytotoxic therapy and the PARP inhibitor veliparib in metastatic castration resistant prostate cancer – a case report

Solid tumors harboring BRCA1 or BRCA2 mutations have been shown to respond to PARP inhibitors. These responses are partial and transient. In this case report we describe an 80-yr old male with poorly differentiated prostate cancer with metastases to the lung, liver, abdomen, and bowel. Molecular...

Full description

Bibliographic Details
Main Authors: David J VanderWeele, Gladell P Paner, Gini F Fleming, Russell Z Szmulewitz
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-07-01
Series:Frontiers in Oncology
Subjects:
prostate cancer
BRCA2
TP53
complete response (CR)
veliparib
PARP inhibitors (PARPi)
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00169/full

Similar Items

Similar Items